NYSE - Delayed Quote USD

Elanco Animal Health Incorporated (ELAN)

13.44
-0.08
(-0.59%)
At close: May 30 at 4:00:02 PM EDT
13.44
0.00
(0.00%)
After hours: May 30 at 6:12:43 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Jeffrey N. Simmons President, CEO & Director 2.83M -- 1967
Mr. Todd S. Young J.D. Executive VP & CFO 1.29M -- 1972
Dr. Ramiro Martin Cabral Executive VP & President of Elanco International 1.13M -- 1972
Dr. Ellen de Brabander Ph.D. Executive Vice President of Research, Development & Regulatory Affairs 1.37M -- 1963
Mr. Timothy J. Bettington Executive Vice President of Corporate Strategy & Market Development 1.13M -- 1974
Mr. James M. Meer Senior VP & Chief Accounting Officer -- -- 1970
Mr. Chris Keeley Senior VP & Chief Information Officer -- -- --
Mr. David S. Kinard Executive Vice President of Human Resources, Corporate Communications & Administration 722.58k -- 1967
Ms. Shiv O'Neill Executive Vice President, General Counsel & Corporate Secretary -- -- 1975
Mr. Larbi Van Lier Senior Vice President of Asia -- -- --

Elanco Animal Health Incorporated

2500 Innovation Way
Greenfield, IN 46140
United States
877 352 6261 https://www.elanco.com
Sector: 
Healthcare
Full Time Employees: 
9,000

Description

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Corporate Governance

Elanco Animal Health Incorporated’s ISS Governance QualityScore as of June 1, 2025 is 5. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 2; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 7, 2025 at 11:30 AM UTC

Elanco Animal Health Incorporated Earnings Date

Recent Events

May 30, 2025 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 28, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 27, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 17, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 25, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers